Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 10, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-17
DOI
10.1038/s41408-020-00340-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
- (2019) Emmanuel Bachy et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study
- (2018) Brian K. Link et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
- (2018) Stefano Luminari et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
- (2017) Mariano Provencio et al. PLoS One
- Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
- (2016) Matthew J. Maurer et al. AMERICAN JOURNAL OF HEMATOLOGY
- Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era
- (2016) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial
- (2016) Clémentine Sarkozy et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)
- (2015) N. D. Wagner-Johnston et al. BLOOD
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
- (2014) Kirit M Ardeshna et al. LANCET ONCOLOGY
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
- (2013) D. Tan et al. BLOOD
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource
- (2013) Brian K. Link et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
- (2012) A. K. Nooka et al. ANNALS OF ONCOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting
- (2009) S. A. M. van de Schans et al. ANNALS OF ONCOLOGY
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
- (2009) Massimo Federico et al. JOURNAL OF CLINICAL ONCOLOGY
- Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
- (2008) Abdulwahab J. Al-Tourah et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now